dc.contributor.author | Sorriento, Daniela | |
dc.contributor.author | Illario, Maddalena | |
dc.contributor.author | Finelli, Rosa | |
dc.contributor.author | Iaccarino, Guido | |
dc.date.accessioned | 2013-05-29T09:58:33Z | |
dc.date.available | 2013-05-29T09:58:33Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Sorriento D, Illario M, Finelli R, Iaccarino G. To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator. Translational Medicine @ UniSa 2012;4(9):73-85 | en_US |
dc.identifier.issn | 2239-9747 | en_US |
dc.identifier.uri | http://hdl.handle.net/10556/639 | |
dc.description.abstract | Nuclear factor B (NFB) is a transcription
factor that plays an important role in carcinogenesis as well
as in the regulation of inflammatory response. NFB is
constitutively expressed in tumours where it induces the
expression of genes which promote cell proliferation,
apoptotic events, angiogenesis, invasion and metastasis.
Furthermore, many cancer cells show aberrant or
constitutive NFB activation that mediates resistance to
chemo- and radio-therapy. Therefore, the inhibition of NFB
activity appears a potential therapeutic strategy for cancer
treatment. In this review, we focus on the role of NFB in
carcinogenesis and summarize actual inhibitors of NFB that
could be potential therapeutic target in cancer therapy. | en_US |
dc.format.extent | P. 73-85 | en_US |
dc.language.iso | en | en_US |
dc.source | UniSa. Sistema Bibliotecario di Ateneo | en_US |
dc.subject | Transcription factors | en_US |
dc.subject | IkB | en_US |
dc.subject | GRK5 | en_US |
dc.subject | Cancer | en_US |
dc.title | To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator | en_US |
dc.type | Article | en_US |